Abstract: Methods of treating or preventing the growth of Candida albicans (“C. albicans”) using cannabinoid compounds are described herein. The cannabinoid compounds can include one or more of cannabidivarin (“CBDV”), cannabidiorcol (“CBD-C1”), cannabidol-C2 (“CBD-C2”), cannabidol-C4 (“CBD-C4”), cannabigerivarin (“CBGV”), cannabidol (“CBD”), and cannabigerol butyl (“CBG-C4”). The methods can be used to treat or prevent oral thrush, athlete's foot, vaginal (yeast) infections, systemic infections, and other infections. Compositions and articles including the cannabinoid compounds are further disclosed.

Abstract: Compositions for regulating gastric acid buildup using cannabinoid compounds are described herein. The cannabinoid compounds can include one or more of cannabicyclol (“CBL”), cannabichromene (“CBC”), cannabidivarin (“CBDV”), cannabidol (“CBD”), cannabigerol hexyl (“CBG-C6”), cannabigerol heptyl (“CBG-C7”), cannabigerol nonyl (“CBG-C9”), cannabidol-C2 (“CBD-C2”), cannabidol hexyl (“CBD-C6”), and cannabidol heptyl (“CBD-C7”). The cannabinoid compounds can be H2 antagonists. Methods and articles including the cannabinoid compounds are further disclosed.

Abstract: Methods of inhibiting the growth of Porphyromonas gingivalis (“P. gingivalis”) in the oral cavity using cannabinoid compounds are described herein. The cannabinoid compounds can include one or more of cannabinol cannabigerol (“CBG”), cannabigerolic acid (“CBGA”), cannabidiolic acid (“CBDA”), and (+)-cannabidiol (“((+)-CBD”), cannabichromene (“CBC”), cannabinol (“CBN”), cannabidivarin (“CBDV”), cannabidol (“CBD”), cannabidol-C4 (“CBD-C4”), cannabigerivarin (“CBGV”), cannabigerol butyl (“CBG-C4”), cannabichromenic acid (“CBCA”), cannabicyclolic acid (“CBLA”), and cannabinolic acid (“CBNA”), cannabidol-C2 (“CBD-C2”) and cannabigerolic acid butyl (“CBGA-C4”). The methods can be used to treat or prevent periodontal disease. Compositions and articles including the cannabinoid compounds are further disclosed.

Abstract: Methods of improving the stability of a non-petroleum oil using cannabinoid compounds are described herein. The cannabinoid compounds can include cannabigerol (“CBG”) and/or cannabigerolic acid (“CBGA”). The cannabinoid compounds can be antioxidants. Compositions and articles including the cannabinoid compounds are further disclosed.

Abstract: Methods of treating itching with cannabinoid compounds are described herein. The cannabinoid compounds can include one or more of cannabidol (“CBD”), cannabichromene (“CBC”), cannabigerol (“CBG”), cannabinol (“CBN”), cannabicyclol (“CBL”), cannabidivarin (“CBDV”), cannabigerivarin (“CBGV”), and cannabicyclolic acid (“CBLA”) and variants thereof. The cannabinoid compounds can be antagonists to the receptors CHRM2, EDG3, and MRGPRX2. Compositions and articles including the cannabinoid compounds are further disclosed.

Abstract: Methods of regulating or treating the sleep/wake cycle and related sleep disorders with cannabinoid compounds are described herein. The cannabinoid compounds can include one or more of cannabichromene (“CBC”), cannabicyclol (“CBL”), cannabinol (“CBN”), tetrahydrocannabivarin (“THCV”), cannabidol (“CBD”), (+)-cannabidiol (“(+)-CBD”), cannabigerol (“CBG”), and cannabigerol butyl (“CBG-C4”) and can be antagonists to the receptors HCRTR1 and HCTR2. Compositions and articles including the cannabinoid compounds are further disclosed.

Abstract: The present disclosure relates to compositions and methods for reducing, preventing, and/or treating skin conditions comprising the administration of one or more cannabidiols. Specifically, the present disclosure relates to compositions comprising CBG or CBGVA for the reduction of aging.

Abstract: The present disclosure relates to compositions and methods for reducing, preventing, and/or treating oral conditions comprising the administration of one or more cannabidiols. Specifically, the present disclosure relates to compositions comprising CBG, CBGVA or combinations thereof for the reduction of oral inflammation.

Abstract: The present disclosure relates to compositions and methods for reducing, preventing, and/or treating oral conditions comprising the administration of one or more cannabinoid compounds to reduce Streptococcus mutans. The one or more cannabinoid compounds can include cannabigerol (“CBG”), cannabigerolic acid (“CBGA”), cannabichromene (“CBC”), cannabidivarinic acid (“CBDVA”), cannabidivarin (“CBDV”), cannabidiolic acid (“CBDA”), cannabidiol (“CBD”), cannabidiol ethyl (“CBD-C2”), cannabidibutol (“CBD-C4”), (+)-cannabidiol (“(+)-CBD”), cannabigerovarin (“CBGV”), cannabigerol butyl (“CBG-C4”), or cannabigerolic acid butyl (“CBGA-C4”). Methods of making and using the cannabinoid compounds are further disclosed.